Meeting
2023 ASCO Breakthrough
Heterogeneity of PD-L1 expression among resected EGFR-mutated NSCLC and prognostic implications.
Authors
Stephanie Pei Li Saw
National Cancer Centre Singapore, Singapore, Singapore
Stephanie Pei Li Saw , Nwe Oo Hlaing , Siqin Zhou , Anne James , Gillianne Lai , Darren Wan-Teck Lim , Ravindran Kanesvaran , Quan Sing Ng , Amit Jain , Wan Ling Tan , Johan Chan , Yi Lin Teh , Wei Chong Tan , Aaron C. Tan , Boon-Hean Ong , Tony Kiat Hon Lim , Sze Huey Tan , Angela M. Takano , Daniel Shao-Weng Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Diagnostics
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 143)
DOI
10.1200/GO.2023.9.Supplement_1.143
Abstract #
143
Poster Bd #
H5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.
First Author: Petros Christopoulos
Poster
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
First Author: Biagio Ricciuti
Poster
2022 ASCO Annual Meeting
Observer performance study to examine the feasibility of the AI-powered PD-L1 analyzer to assist pathologists’ assessment of PD-L1 expression using tumor proportion score in non–small cell lung cancer.
First Author: Seokhwi Kim
Poster
2021 ASCO Annual Meeting
Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC).
First Author: Hyojin Kim